Cardio3 Biosciences Embedded BioLife Solutions for a Heart Regenerative Therapy

11/04/2015 - 2 minutes

Cardio3 BioSciences is again on the front page of biotech news. After announcing the launching of an IPO on Nasdaq and getting an US patent, the company has now embedded the BioLife Solutions‘ clinical grade CryoStor cryopreservation freeze media, in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States.

CHART-1 is a patient prospective, controlled multi-centre, randomized, double-blinded phase III clinical trial comparing treatment with C-Cure to a sham treatment. Cardio3 BioSciences’ C-Cure therapy involves taking stem cells from a patient’s own bone marrow and through a proprietary process called Cardiopoiesis, re-programming those cells to become heart cells. The cells, known as cardiopoietic cells, are then injected back into the patient’s heart through a minimally invasive procedure, with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member